Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Tumor Virology

Prof. Dr. Dr. h. c. Ralf Bartenschlager (in ch.)

Treatment of an intracerebral rat glioma with parvovirus H-1 (H-1PV). MRI of a rat brain bearing a glioma, at the time of infection with H-1PV (left), and 8 days later (right), showing disappearance of the tumor after infection.

Our Division is focused on “Anti-Tumor Virology”, the objective being to develop oncolytic viruses (preferentially killing tumor cells) and viral vectors (transferring therapeutic genes into cancer cells). Our activities have led to the launching of the first virotherapy clinical trial in Germany, using the oncolytic parvovirus H-1PV to treat malignant gliomas. Based on virus safety and first signs of anti-tumor activity, a second clinical study of H-1PV in pancreatic cancer patients and several compassionate trials of H-1PV-based combination therapy are currently performed. Four main research & development axes are presently being followed.

1. Basic investigations of the interactions of oncolytic parvoviruses (PV) with host cells are more particularly focused on (i) the molecular pathways involved in PV oncotoxic properties, (ii) the mechanisms by which PV oncolysis triggers antitumor immune responses, (iii) the identification of cellular markers predictive of tumor responsiveness to PV treatment.
2. Preclinical assessment of the anticancer potential of PV includes (i) evaluating the applicability of PV therapy to malignancies in children and adolescents, (ii) developing novel anticancer strategies based on second generation PV (vectors) and combination treatments, (iii) producing recombinant PV for the delivery of cyto- and chemokines into tumors and their microenvironment.
3. A research program accompanying above-mentioned clinical studies of H-1PV in cancer patients has been implemented to analyze both virus and tumor fates after treatment.
4. Our Virus Production & Development Unit standardizes protocols for virus application to humans, and participates in trial-accompanying research.

Basic research will be pursued to unravel the cellular and parvoviral determinants of permissiveness and killing, respectively. This program is expected to contribute to identifying patients susceptible to oncolytic virus-based treatments (“customized” therapy). Furthermore, our ambition is also to understand and optimize the interplay between parvovirus oncolytic effects and host anti-tumor immune responses. On the translational level, our work aims to broaden the range of indications for a potential H-1PV-based oncolytic virotherapy, and to increase the oncosuppressive capacity of PV through adaptation and engineering. Furthermore, in order to prepare future clinical trials, optimal treatment strategies combining parvoviruses with different classes of antineoplastic and immunomodulating agents will be tested, using various in vitro and in vivo models. Another focus of the Division lies on research accompanying the clinical trials of H-1 parvovirus in cancer patients. Of particular interest is the investigation of viral effects not only on the neoplastic compartment but also on the tumor microenvironment modulating anti-cancer immune responses.


Prof. Dr. Dr. h. c. Ralf Bartenschlager (in ch.)
Tumor Virology (F010)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 242
69120 Heidelberg
Tel: +49 6221 42 4970
Fax: +49 6221 42 4962

Selected Publications

  • Geletneky K. et al. (2017). Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. Mol Ther, 25 (12), in press.
  • Bär S. et al. (2015). PKCn/Rdx-driven phosphorylation of PDK1: a novel mechanism promoting cancer cell survival and permissiveness for parvovirus-induced lysis. PLoS Pathog, 11 (3): e1004703.
  • Geletneky K. et al. (2015). Double-faceted mechanism of parvoviral oncosuppression. Curr Opin Virol, 13, 17-24.
  • Li J. et al. (2013). Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med, 5 (10), 1537-1555.
to top
powered by webEdition CMS